Completed PHASE4 INTERVENTIONAL 3-arm NCT00926965

Tardive Dyskinesia and Cognitive Function (TD)

Sponsor: National Science and Technology Council, Taiwan

Conditions Neurocognitive Function Tardive Dyskinesia

Interventions Conventional antipsychotics Olanzapine amisulpride

Updated 7 times since 2017 Last updated: Jun 23, 2009 Started: Jan 31, 2003 Primary completion: Dec 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Neurocognitive Function and Tardive Dyskinesia, this trial is completed. The trial is conducted by National Science and Technology Council, Taiwan and has accumulated 7 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Jun 2025 — Sep 2025 [monthly]

Completed PHASE4
Sep 2024 — Jun 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Science and Technology Council, Taiwan
Taipei Veterans General Hospital, Taiwan

Data source: Taipei Veterans General Hospital, Taiwan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hualien City, Taiwan